1
|
Lazarian G, Theves F, Hormi M, Letestu R, Eclache V, Bidet A, Cornillet‐Lefebvre P, Davi F, Delabesse E, Estienne M, Etancelin P, Kosmider O, Laibe S, Lode L, Muller M, Nadal N, Naguib D, Pastoret C, Poulain S, Sujobert P, Veronese L, Imache S, Lefebvre V, Cymbalista F, Baran‐Marszak F, Soussi T. TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia. Am J Hematol 2022; 97:E159-E162. [PMID: 35083778 DOI: 10.1002/ajh.26479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Accepted: 01/21/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Grégory Lazarian
- Service d'hématologie biologique GHUPPSD, Hopital Avicenne, Université Sobonne Paris Nord, INSERM U978 Bobigny France
| | | | - Myriam Hormi
- Service d'hématologie biologique GHUPPSD, Hopital Avicenne, Université Sobonne Paris Nord, INSERM U978 Bobigny France
| | - Rémi Letestu
- Service d'hématologie biologique GHUPPSD, Hopital Avicenne, Université Sobonne Paris Nord, INSERM U978 Bobigny France
| | - Virginie Eclache
- Service d'hématologie biologique GHUPPSD, Hopital Avicenne, Université Sobonne Paris Nord, INSERM U978 Bobigny France
| | - Audrey Bidet
- Service d'hématologie biologique CHU Bordeaux‐Haut Lévêque Bordeaux France
| | | | - Frédéric Davi
- Service d'hématologie biologique CHU Pitié Salpétrière Paris France
| | - Eric Delabesse
- Service d'hématologie biologique CHU Toulouse Toulouse France
| | | | | | - Olivier Kosmider
- Service d'hématologie biologique CHU Hopital Cochin Paris France
| | | | - Laurence Lode
- Laboratoire d'oncobiologie CHU Montpellier Montpellier France
| | - Marc Muller
- Laboratoire de génétique médicale CHU Nancy Hôpitaux de Brabois Vandoeuvre‐lès‐Nancy France
| | - Nathalie Nadal
- Service de génétique chromosomique et moléculaire CHU Dijon Dijon France
| | - Dina Naguib
- Service d'hématologie biologique CHU Caen Caen France
| | | | | | - Pierre Sujobert
- Service d'Hématologie Cellulaire Hospices civils de Lyon Lyon France
| | - Lauren Veronese
- Service de cytogénétique médicale CHU Clermont‐Ferrand Clermont‐Ferrand France
| | - Samia Imache
- Service d'hématologie biologique GHUPPSD, Hopital Avicenne, Université Sobonne Paris Nord, INSERM U978 Bobigny France
| | - Valérie Lefebvre
- Service d'hématologie biologique GHUPPSD, Hopital Avicenne, Université Sobonne Paris Nord, INSERM U978 Bobigny France
| | - Florence Cymbalista
- Service d'hématologie biologique GHUPPSD, Hopital Avicenne, Université Sobonne Paris Nord, INSERM U978 Bobigny France
| | - Fanny Baran‐Marszak
- Service d'hématologie biologique GHUPPSD, Hopital Avicenne, Université Sobonne Paris Nord, INSERM U978 Bobigny France
| | - Thierry Soussi
- Centre de Recherche des Cordeliers Sorbonne Université, Inserm, Cell Death and Drug Resistance in Lymphoproliferative Disorders Paris France
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory Uppsala University Uppsala Sweden
| | | |
Collapse
|
2
|
Bou-Hanna C, Jarry A, Lode L, Schmitz I, Schulze-Osthoff K, Kury S, Bezieau S, Mosnier JF, Laboisse CL. Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis. Cancer Lett 2015; 359:211-7. [PMID: 25617798 DOI: 10.1016/j.canlet.2015.01.014] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Revised: 01/09/2015] [Accepted: 01/13/2015] [Indexed: 12/25/2022]
Abstract
Although numerous studies have focused on the mechanisms of action of the candidate chemotherapeutic drug MIRA-1/NSC19630, initially described as a mutant p53-reactivating small molecule, the issue of its toxicological evaluation remains open. Here, we devised a strategy to examine the effects of MIRA-1 on a variety of human normal cells and cancer cell lines. First, we demonstrated a massive and rapid (within 2 hours) MIRA-1 apoptotic effect on human normal primary epithelial cells as shown using an intestinal mucosa explant assay. MIRA-1 was also cytotoxic to primary and subcultured human mesenchymal cells. Interestingly these effects were restricted to actively proliferating cells. Second, MIRA-1 acute toxicity was independent of p53, since it occurred in human normal cells with increased or silenced p53 expression level, in cancer cells derived from solid or liquid tumors, with either mutated or wt TP53, and in cancer cells devoid of p53. Third, combined pharmacological and genetic approaches showed that MIRA-1 acute cytotoxicity was mediated by a caspase-9-dependent apoptosis. In conclusion, our strategy unveils the limitations of the targeted action of a small molecule designed to reactivate mutant p53.
Collapse
Affiliation(s)
- Chantal Bou-Hanna
- EA4273 Biometadys, Faculté de Médecine, Université de Nantes, France
| | - Anne Jarry
- EA4273 Biometadys, Faculté de Médecine, Université de Nantes, France
| | | | - Ingo Schmitz
- Systems-Oriented Immunology and Inflammation Research, Helmholtz Center for Infection Research, Braunschweig, Germany; Institute for Molecular and Clinical Immunology, Otto-von-Guericke University, Magdeburg, Germany
| | | | - Sébastien Kury
- Service de Génétique Médicale, CHU de Nantes, Nantes, France
| | - Stéphane Bezieau
- EA4273 Biometadys, Faculté de Médecine, Université de Nantes, France; Service de Génétique Médicale, CHU de Nantes, Nantes, France
| | - Jean-François Mosnier
- EA4273 Biometadys, Faculté de Médecine, Université de Nantes, France; Service d'Anatomie et Cytologie Pathologiques, CHU de Nantes, France
| | - Christian L Laboisse
- EA4273 Biometadys, Faculté de Médecine, Université de Nantes, France; Service d'Anatomie et Cytologie Pathologiques, CHU de Nantes, France.
| |
Collapse
|
3
|
Adamia S, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Burke J, Galinsky I, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone R, Griffin JD. A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res 2013; 20:1135-45. [PMID: 24284058 DOI: 10.1158/1078-0432.ccr-13-0956] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
PURPOSE Despite new treatments, acute myeloid leukemia (AML) remains an incurable disease. More effective drug design requires an expanded view of the molecular complexity that underlies AML. Alternative splicing of RNA is used by normal cells to generate protein diversity. Growing evidence indicates that aberrant splicing of genes plays a key role in cancer. We investigated genome-wide splicing abnormalities in AML and based on these abnormalities, we aimed to identify novel potential biomarkers and therapeutic targets. EXPERIMENTAL DESIGN We used genome-wide alternative splicing screening to investigate alternative splicing abnormalities in two independent AML patient cohorts [Dana-Farber Cancer Institute (DFCI) (Boston, MA) and University Hospital de Nantes (UHN) (Nantes, France)] and normal donors. Selected splicing events were confirmed through cloning and sequencing analysis, and than validated in 193 patients with AML. RESULTS Our results show that approximately 29% of expressed genes genome-wide were differentially and recurrently spliced in patients with AML compared with normal donors bone marrow CD34(+) cells. Results were reproducible in two independent AML cohorts. In both cohorts, annotation analyses indicated similar proportions of differentially spliced genes encoding several oncogenes, tumor suppressor proteins, splicing factors, and heterogeneous-nuclear-ribonucleoproteins, proteins involved in apoptosis, cell proliferation, and spliceosome assembly. Our findings are consistent with reports for other malignances and indicate that AML-specific aberrations in splicing mechanisms are a hallmark of AML pathogenesis. CONCLUSIONS Overall, our results suggest that aberrant splicing is a common characteristic for AML. Our findings also suggest that splice variant transcripts that are the result of splicing aberrations create novel disease markers and provide potential targets for small molecules or antibody therapeutics for this disease.
Collapse
Affiliation(s)
- Sophia Adamia
- Authors' Affiliations: Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Bioinformatics and Computational Genomics Laboratory, Institut de Recherches Cliniques de Montréal, Montreal, Quebec, Canada; Department of Computing Science, University of Alberta, Edmonton, Alberta, Canada; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Center for Cancer Systems Biology and Department of Genetics, Harvard Medical School, Boston University School of Medicine and Biomedical Engineering Department, Boston University, Boston, Massachusetts; Unité de Génomique du Myélome, Laboratoire UGM, University Hospital, CHU Rangueil, Toulouse, France; Hematology Laboratory, University Hospital; and INSERM U892, Nantes, France; Molecular Diagnostics Laboratory, Dana Farber Cancer Institute, Boston, Massachusetts; Biotique Systems Inc., www.biotiquesystems.com; Adult Leukemia Program, Dana Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. Biol Blood Marrow Transplant 2013; 19:934-9. [PMID: 23523970 DOI: 10.1016/j.bbmt.2013.03.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Accepted: 03/18/2013] [Indexed: 02/07/2023]
Abstract
Recent advances in allogeneic stem cell transplantation (allo-HSCT) have included the advent of reduced-intensity conditioning (RIC) regimens to decrease the toxicity of myeloablative allo-SCT and the use of double umbilical cord blood (dUCB) units as a graft source in adults lacking a suitable donor. The FB2A2 regimen (fludarabine 30 mg/kg/day for 5-6 days + i.v. busulfan 3.6 mg/kg/day for 2 days + rabbit antithymocyte globulin 2.5 mg/kg/day for 2 days) supported by peripheral blood stem cells (PBSCs) and the TCF regimen (fludarabine 200 mg/m² for 5 days + cyclophosphamide 50 mg/kg for 1 day + low-dose [2 Gy] total body irradiation) supported by dUCB units are currently the most widely used RIC regimens in many centers and could be considered standard of care in adults eligible for an RIC allo-SCT. Here we compared, retrospectively, the outcomes of adults patients who received the FB2A2-PBSC RIC regimen (n = 52; median age, 59 years; median follow-up, 19 months) and those who received the dUCB-TCF RIC regimen (n = 39; median age, 56 years; median follow-up, 20 months) for allo-SCT between January 2007 and November 2010. There were no significant between-group differences in patient and disease characteristics. Cumulative incidences of engraftment, acute grade II-IV and chronic graft-versus-host disease were similar in the 2 groups. The median time to platelet recovery, incidence of early death (before day +100), and 2-year nonrelapse mortality were significantly higher in the dUCB-TCF group (38 days versus 0 days [P <.0001]; 20.5% versus 4% [P = .05], and 26.5% versus 6% [P = .02], respectively). The groups did not differ in terms of 2-year overall survival (62% for FB2A2-PBSC versus 61% for dUCB-TCF), disease-free survival (59% versus 50.5%), or relapse incidence (35.5% versus 23%). In multivariate analysis, the presence of a lymphoid disorder was associated with a significantly higher 2-year overall survival (hazard ratio, 0.42; 95% confidence interval, 0.20-0.87; P = .02), whereas patients receiving a FB2A2-PBSC allo-SCT had a significantly lower 2-year nonrelapse mortality (hazard ratio, 0.24; 95% confidence interval, 0.1-0.7; P = .01). There were no factors associated with higher 2-year disease-free survival or lower relapse incidence. This study suggests that the dUCB-TCF regimen provides a valid alternative in adults lacking a suitable donor and eligible for RIC allo-SCT. Prospective and randomized studies are warranted to establish the definitive role of dUCB RIC allo-SCT in adults. In addition, strategies for decreasing nonrelapse mortality after dUCB RIC allo-SCT are urgently needed.
Collapse
|
5
|
Lee SG, Cho SY, Kim MJ, Oh SH, Cho EH, Lee S, Baek EJ, Choi JH, Bohlander SK, Lode L, Richebourg S, Yoon HJ, Marschalek R, Meyer C, Park TS. Genomic breakpoints and clinical features of MLL-TET1 rearrangement in acute leukemias. Haematologica 2012; 98:e55-7. [PMID: 23100278 DOI: 10.3324/haematol.2012.076323] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
6
|
Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, Filanovsky K, Cornillet-Lefebvre P, Luquet I, Lode L, Richebourg S, Blanchet O, Gachard N, Vey N, Ifrah N, Milpied N, Harousseau JL, Bene MC, Mohty M, Delaunay J. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia 2011; 25:939-44. [PMID: 21331073 DOI: 10.1038/leu.2011.25] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A simplified prognostic score is presented based on the multivariate analysis of 138 refractory/relapsed acute myeloid leukaemia (AML) patients (median age 55 years, range: 19-70) receiving a combination of intensive chemotherapy+Gemtuzumab as salvage regimen. Overall, 2-year event-free survival (EFS) and overall survival (OS) were 29±4% and 36±4%, respectively. Disease status (relapse <12 months, including refractory patients), FLT3-ITD-positive status and high-risk cytogenetics were the three strongest independent adverse prognostic factors for OS and EFS in this series. We then defined three subgroups with striking different outcomes at 2 years: no adverse factor (favourable, N=36): OS 58%, EFS 45%; one adverse factor (intermediate, N=54): OS 37%, EFS 31%; two or three adverse factors (poor, N=43): OS 12%, EFS 12% (P<10(-4), P=0.001). This new simplified Leukemia Prognostic Scoring System was then validated on an independent cohort of 111 refractory/relapsed AML patients. This new simplified prognostic score, using three clinical and biological parameters routinely applied, allow to discriminate around two third of the patients who should benefit from a salvage intensive regimen in the setting of refractory/relapsed AML patients. The other one third of the patients should receive investigational therapy.
Collapse
Affiliation(s)
- P Chevallier
- Service d'Hématologie Clinique, CHU and Université de Nantes, INSERM U892, Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|